机器人辅助肿瘤细胞减灭术联合腹腔热灌注化疗:低负荷腹膜癌的微创入路
本文回顾性报道单中心连续10例机器人辅助肿瘤细胞减灭术联合腹腔热灌注化疗(R-CRS-HIPEC)的经验,病例选择依据既往腹腔镜评估的腹膜癌指数(PCI<10),并与机器人时代前18例开放CRS-HIPEC(均为PCI<10、阑尾来源肿瘤)进行手术结局比较。结果显示无围术期并发症,全部患者术后7天内出院;作者认为对高度选择的阑尾黏液性肿瘤患者该术式安全可行,低腹腔肿瘤负荷是采用机器人入路的必要前提。
要点
- R-CRS-HIPEC仅适用于经既往腹腔镜证实PCI<10的低负荷腹膜癌患者。
- 10例R-CRS-HIPEC无围术期并发症,均在术后7天内出院。
- 阑尾黏液性肿瘤且腹腔肿瘤负荷低是机器人入路的必要前提。
核心结论
- 对高度选择的阑尾黏液性肿瘤患者,机器人辅助CRS-HIPEC安全可行。
- 低腹腔肿瘤负荷是采用机器人入路行CRS-HIPEC的必要前提。
- 作者支持继续开展该技术的前瞻性临床研究。
研究设计与样本
- 回顾性单中心病例系列,连续纳入10例机器人辅助CRS-HIPEC(R-CRS-HIPEC)患者。
- 术前完善影像学检查并经多学科团队讨论进行病例选择。
- 对照组为机器人时代前连续18例开放CRS-HIPEC患者,均PCI<10且组织学为阑尾来源肿瘤。
主要发现
- 10例R-CRS-HIPEC患者未出现围术期并发症。
- 全部患者均在术后7天内出院。
- 原文未报告两组的其他手术结局对比数值。
关键数值与推荐
- 仅对既往腹腔镜证实PCI<10的局限性腹膜癌患者考虑微创机器人CRS-HIPEC。
- 以肿瘤细胞减灭完整度(CC)于切除后评估腹腔残余病灶。
- 对照人群均为PCI<10且组织学符合阑尾来源肿瘤的连续患者。
临床怎么用
- 术前通过腹腔镜评估PCI,严格筛选PCI<10的低负荷患者进入机器人CRS-HIPEC。
- 以多学科团队讨论作为病例选择流程的一部分。
- 机器人CRS-HIPEC应在具备相应技术条件的中心开展并纳入研究性随访。
局限性
- 回顾性设计,样本量小(机器人组10例)。
- 对照组来自机器人时代前,非同期比较。
- 原文未报告长期肿瘤学结局与随机对照证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Peritoneal carcinomatosis (PC) presents a significant challenge and is often associated with poor prognosis. Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) stands as a well-established treatment modality for various forms of PC. The peritoneal cancer index (PCI) is used to assess the intraperitoneal disease burden, with evidence suggesting a linear correlation with overall survival, particularly in colorectal cancers with peritoneal metastasis. Similarly, completeness of cytoreduction (CC) is assessed post-resection to quantitatively measure residual disease in the abdomen. There has been a growing trend toward minimally invasive CRS-HIPEC, though achieving an accepted CC using this approach has been less frequently reported. This article describes the experience at our institution after ten cases of robotic-assisted CRS-HIPEC. MATERIALS AND METHODS: Data from the ten consecutive R-CRS-HIPEC were retrospectively collected. Comprehensive preoperative imaging and multidisciplinary team deliberations were conducted for case selection. Mini-invasive robotic CRS-HIPEC was considered only for patients exhibiting a limited amount of PC, as evidenced by prior laparoscopy (PCI < 10). To compare surgical outcomes with a homogeneous population of patients undergoing open CRS and HIPEC, 18 consecutive patients treated in the pre-robotic era were retrospectively included, all with PCI < 10 and histology consistent with appendiceal-origin neoplasms. RESULTS: No perioperative complications were noted, and all patients were discharged within seven days of the operation. CONCLUSIONS: Robotic-assisted CRS-HIPEC for appendiceal mucinous neoplasms in highly selected patients is a safe and feasible procedure. A low intraperitoneal tumor burden in patients with intraperitoneal mucinous neoplasms emerges as a mandatory prerequisite to approach CRS-HIPEC with a robotic approach. We endorse ongoing investigation and future prospective clinical trials employing this technique.
引用
- Bertolucci A, Ramacciotti N, Piccini L, et al. Robotic-assisted cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a minimally invasive approach for peritoneal carcinomatosis in patients with low burden disease. Surg Endosc. 2026. PMID: 42265291. doi:10.1007/s00464-026-12975-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。